Activating BRAF or NRAS mutations have been found in 80% of human sporadic melanomas, but only one of these genetic alterations could be detected in each tumour. This suggests that BRAF and NRAS 'double mutants' may not provide advantage for tumour growth, or may even be selected against during tumorigenesis. However, by applying mutant-allele-specific-amplification-PCR method to short-term melanoma lines, one out of 14 tumours was found to harbour both BRAF V600E and the activating NRAS Q61R mutations. On the other hand, analysis of 21 melanoma clones isolated by growth in soft agar from this tumour indicated that 16/21 clones harboured a BRAF
Introduction
The RAS/RAF/MEK/ERK signalling kinase cascade that transduces extra cellular mitogenic signals to the cell nucleus has been shown to be constitutively activated in human cutaneous melanoma due either to oncogenic mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) or NRAS (neuroblastoma RAS viral oncogene homolog), or through autocrine growth factor stimulation (Satyamoorthy et al., 2003; Smalley, 2003; Sebolt-Leopold and Herrera, 2004) .
The BRAF gene encodes a serine/threonine kinase, which couples signalling from activated RAS to downstream MAPK kinases (Wellbrock et al., 2004) . Mutations in the BRAF gene mainly affect exons 11 and 15 encoding the kinase activation domain (Davies et al., 2002; Mercer and Pritchard, 2003; Garnett and Marais, 2004) and are found at high frequency (60% of cases) in human melanoma. In more than 90% of melanomas with a mutated BRAF, a single-base mutation at nucleotide position 1799 of exon 15 leads to a valine to glutamate (V600E) substitution (Davies et al., 2002; Mercer and Pritchard, 2003; Garnett and Marais, 2004; Gray-Schopfer et al., 2005) . This mutation (BRAF V600E ) significantly increases kinase activity of BRAF and induces constitutive ERK phosphorylation and focus formation in NIH3T3 cells (Davies et al., 2002; Garnett and Marais, 2004; Wan et al., 2004) . In melanoma, depletion of mutant BRAF by RNA interference (RNAi) techniques has been shown to inhibit MAPK cascade, to cause growth arrest, to promote apoptosis and to abrogate transformation (for a review see GraySchopfer et al., 2005) . Although benign nevi also display BRAF
V600E
, recent data suggest that such mutation is more frequent in growing nevi that tend to progress to malignancy (Pollock et al., 2003; Loewe et al., 2004) .
Activating mutations in the NRAS gene are the other prevalent genetic hallmark of melanomas, occurring in more than 20% of primary and more than 30% of metastatic melanomas, and mainly in lesions from sunexposed sites (Ball et al., 1994; Jiveskog et al., 1998; Omholt et al., 2003) . The most common point mutations affect codon 61 (Q61R and Q61K) and result in the expression of p21RAS oncoproteins with a single substituted amino acid that remain constitutively GTP bound and active (Malumbres and Barbacid, 2003) . Active, GTP-bound RAS protein interact with a wide range of signalling effectors including RAF kinases, phosphatidylinositol 3-kinase (PI3K), Ral-guanine nucleotide exchange factors (Ral-GDS, RGL, RLF and RGL3), NORE/RASSF1 and phospholipase C (Repasky et al., 2004) .
In spite of the biological relevance of the RAS/RAF/ MEK/ERK signalling cascade and of the high frequency of mutated BRAF or NRAS in human melanoma, simultaneous presence of BRAF and NRAS mutations in the same tumour are rare (Garnett and Marais, 2004) . Moreover, in few exceptional cases in which a BRAF mutation was found together with a transforming NRAS mutation, the BRAF mutation did not include the V600E change (Gorden et al., 2003) . Similarly, NRAS mutations detected in BRAF V600E tumours were rare and not transforming (Brose et al., 2002) . These data are consistent with the hypothesis that 'double mutant' tumours, harbouring both activated BRAF and NRAS, may not occur naturally, as such neoplastic cells may either lack a survival advantage, or may even be selected against during tumorigenesis. Unlike melanomas, however, coincident activating mutations in BRAF and NRAS genes have been found in nevi (Pollock et al., 2003) .
To explore the possibility that activating BRAF and NRAS mutations could coexist even in the same melanoma, we adopted the highly sensitive mutantallele-specific-amplification (MASA)-PCR technique (Hasegawa et al., 1995; Linard et al., 2002; Miller et al., 2004) . By screening a panel of 14 human primary and metastatic melanomas, we found one tumour carrying the BRAF V600E mutation together with a transforming NRAS mutation (Q61R). However, BRAF and NRAS mutations were mutually exclusive at the single-cell level, as shown by analysis of melanoma clones isolated from this tumour. Furthermore, we found that BRAF V600E or NRAS Q61R melanoma clones displayed different growth properties in vitro, in soft agar or in liquid medium, and in vivo after injection into SCID mice.
Results
Identification, by MASA-PCR, of a melanoma with concomitant NRAS and BRAF activating mutations Fourteen short-term melanoma cell lines harbouring activating exon 3 NRAS Q61R (7/14 lines) or exon 15 (7/14 tumours) BRAF V600E mutations, as detected by sequence analysis or oligonucleotide hybridization, were chosen for this study (Lupetti et al., 1994; Daniotti et al., 2004) . All these melanoma lines were heterozygous for the mutated NRAS or BRAF genes and retained the corresponding wild-type allele. To evaluate whether some of these lines could carry both NRAS and BRAF mutations, we reanalysed DNA isolated from these tumours for the presence of both mutations using the sensitive MASA-PCR method (Hasegawa et al., 1995; Linard et al., 2002; Miller et al., 2004) . We used published forward primers designed with two mismatches at their 3 0 to amplify mutant NRAS Q61R and BRAF V600E and control forward primers, derived from the wild-type genes to amplify both wild-type and mutant sequences (Linard et al., 2002; Xu et al., 2003) . When MASA-PCR was performed at 35 amplification cycles, no evidence of double-mutated samples was obtained. Figure 1a and (Figure 1d ). All other NRAS Q61R tumours, including two additional metastases of the same patient (665/1 and 665/R) remained negative for the BRAF V600E mutation even when tested at 45 cycles (data not shown).
A titration assay was then performed to compare sensitivity between MASA-PCR and direct fluorescent sequencing (Figure 2 ). To this end, decreasing proportions (10-0.1%) of genomic DNA from a melanoma cell line containing the BRAF V600E mutation (18 732) were added to genomic DNA from a lymphoblastoid cell line (LCL) carrying only the wild-type BRAF allele. Both direct fluorescent sequencing and MASA-PCR were then carried out on all these samples. Direct fluorescent sequencing required at least 10% of mutant DNA in the total mixture to clearly detect BRAF V600E mutation ( Figure 2a ). Below the 10% threshold, the presence of the mutation could not reliably be distinguished from background on the electropherogram. As described by Miller et al. (2004) , standard 35 cycles MASA-PCR detected mutant DNA with higher sensitivity (5%) (Figure 2b , left panel). When the reaction was conducted for 45 cycles ( Figure 2b , right panel) it could provide a specific signal even when the BRAF V600E DNA represented only 0.5% of the template. Taken together these results suggested that a minor subpopulation of cells in melanoma 665/2 carry BRAF V600E at frequency below detectability by most standard methods.
NRAS
Q61R and BRAF V600E mutations are mutually exclusive at the single-cell level To assess whether NRAS and BRAF, found mutated in the same melanoma, could coexist at the single-cell level, we examined, by MASA-PCR as well as by direct sequencing of amplified NRAS exon 3 or BRAF exon 15, 21 clones derived by cloning melanoma 655/2 cells, after a few in vitro passages, by the soft-agar technique (Anichini et al., 1989) . The results obtained with both mutational analysis were concordant and indicated that five of the clones (2/4, 2/14, 2/17, 2/51, 2/60) displayed the activating Q61R mutation at one of the alleles, whereas all remaining clones had wild-type NRAS alleles, in agreement with a previous report (Lupetti et al., 1994) (Table 1 and Figure 3 , for representative results). Strikingly, the BRAF V600E mutation was detected in all clones with wild-type NRAS, whereas clones with mutated NRAS were wild-type for BRAF (Table1 and Figure 3 , for representative results). The possibility that the BRAF mutation could be gained in vitro, as an adaptive response to cell culture or to cloning in soft agar, was ruled out by the analysis of 35 melanoma The segregation of BRAF and NRAS mutations in different cells from the same tumour, and the prevalence of the BRAF V600E mutation in clones isolated in soft agar, suggested that BRAF-and NRAS-mutated clones could have different biological properties. As a first step to test this hypothesis we assayed two BRAF V600E -mutated clones (2/21 and 2/56) and two NRAS Q61R -mutated clones (2/14 and 2/17) for their ability to form colonies in soft agar. Both NRAS Q61R clones demonstrated more than 80% reduction in colony formation compared to the BRAF V600E ones (Figure 4a ). In presence of high (10%) (Figure 4a) . None of the BRAF V600E or NRAS Q61R clones could form colonies either in serum-free conditions or in the presence of 0.1% fetal bovine serum (FCS) (data not shown). Moreover, colonies formed by clones 2/21 and 2/56 were not only present in higher number, but also displayed a larger size (at both 10 and 1% of FCS) compared to colonies produced by clones 2/14 and 2/17 (Figure 4b) . The results of the colony assay with BRAF V600E or NRAS Q61R clones, suggested a differential ability to grow in conditions that, as it happens in soft agar, do not allow cell adhesion to the substrate. In support of this possibility, clones 2/21 and 2/56 exhibited a higher percentage of viable cells compared to 2/14 and 2/17 after culture on Ultra-Lowt (ULC) plates coated with a hydrogel layer that prevents cellular attachment (Figure 4c) . Interestingly, proliferation rates after seeding into standard cell culture dishes that support cell attachment and spreading were higher for NRAS Q61R than for BRAF V600E clones as documented by evaluating 3 H-TdR incorporation (Figure 4d ). With the exception of one condition (72 h, 1% FCS), the measured differences in proliferation rates among the two groups of clones were highly significant.
Differential tumorigenic properties of melanoma clones expressing NRAS
Q61R or BRAF V600E in vivo by grafting into SCID mice To further evaluate the differential growth ability of NRAS-and BRAF-mutated clones from 665/2, cells from seven melanoma clones were injected subcutaneously into SCID mice. NRAS Q61R clones (2/4, 2/14 and 2/17) developed tumours with a shorter latency and with a significantly markedly larger size during the 4 weeks of observation, compared with the tumours formed by BRAF V600E clones (2/30, 2/43, 2/56, 2/59) ( Figure 5a ). Subcutaneous tumours deriving from each clone were excised from two mice 30 days after tumour injection. DNA was extracted and amplified by MASA-PCR confirming the derivation of each tumour from the corresponding NRAS Q61R or BRAF V600E clones (data not shown). Paraffin-embedded sections taken from SCIDgrown tumours were stained with haematoxylin and eosin. Tumours arising from xenografts of NRASmutated clones, even when present as large tumour masses, appeared healthy and viable, whereas the tumour mass of BRAF-mutated clones was occupied by a large necrotic area (see Figure 5b for representative examples taken from xenografts from NRAS Q61R clone 2/17 and BRAF V600E clone 2/56).
Discussion
The results of this study indicate that activating mutations of both NRAS (Q61R) and BRAF (hot-spot codon 600) genes can coexist in the same human melanoma. However, although fluorescent sequencing or standard MASA-PCR (35 cycles) could detect one of the two mutations (NRAS Q61R ), neither of these techniques, including pyrosequencing (Sivertsson et al., 2002) (data not shown), did reach the necessary sensitivity to detect the presence of the second mutation (BRAF V600E ) that could be evidenced only through the use of 45 cycles MASA-PCR. The higher sensitivity level required to detect the BRAF mutation suggested that this genetic lesion affected a minor subpopulation of cells. Our titration experiments confirmed the increased sensitivity of MASA-PCR, even at 35 cycles, compared to conventional sequencing approaches (Miller et al., 2004) . Such experiments further demonstrated that the specificity of MASA-PCR is maintained at high number of cycles (45 cycles) at which it could reliably detect mutated BRAF DNA even when diluted in wild-type DNA at percentages as low as 0.25%, assuming 
NRAS
Q61R and BRAF V600E mutations segregate in a human melanoma M Sensi et al heterozygosity for this allele. Future studies, by exploiting MASA-PCR as well as novel techniques with even greater sensibility (Lilleberg et al., 2004) in large sets of melanoma patients, are needed to assess the true frequency, at the population level, of tumours that contain mutations in both NRAS and BRAF oncogenes.
Concomitant activation of NRAS and BRAF, has been detected in microdissected nevi samples (Pollock et al., 2003) . However, the microdissection technique did not allow assessing whether both alterations could coexist at the same cell level. This could be performed in this study through the mutational analysis of melanoma clones isolated from 665/2 tumour. Our data demonstrate that NRAS Q61R and BRAF V600E mutations in 665/2 melanoma are mutually exclusive at the single-cell level providing further support to the hypothesis that expression of the two mutations may not occur in the same neoplastic cell. Whether concurrent NRAS Q61R and BRAF V600E mutations, if present in the same cell are incompatible with cell survival or contributes to an irreversible growth arrest remains to be determined. Recently, BRAF V600E signalling, through an active oncogene-driven senescence process, has been shown to be an important physiological mechanism limiting the progression of premalignant melanocytic lesions (Michaloglou et al., 2005) .
Our finding should also be considered in the light of ongoing clinical trials in which the inhibitor of threonine/serine kinases Sorafenib (BAY 43-9006), targeting the well-characterized RAF/MEK/ERK RAS-regulated pathway is being evaluated as singletherapy agent or in combination with chemotherapy (Strumberg et al., 2005) . Indeed, this therapeutic strategy may be inadequate for tumours that contain NRAS Q61R -and BRAF
V600E
-mutated subpopulations, as in such instances, the dependence for survival on the RAF/MEK/ERK RAS-regulated pathway will be heterogeneous within the same tumour (Repasky et al., 2004) .
The high number of clones expressing BRAF V600E , compared to NRAS Q61R -mutated clones, found by cloning 665/2 in soft agar, suggested a reduced ability of the latter clones to grow in semi-solid medium. This was confirmed by replating BRAF V600E and NRAS
Q61R
clones in soft agar and by evaluating the number of colonies produced in such setting. The lower colonyforming ability of NRAS Q61R melanoma cells when plated in a semi-solid matrix like soft agar, even in the presence of growth factors provided by 10% FCS, underscores the importance of adhesion for their cellular proliferation. In agreement, NRAS Q61R clones showed a higher proliferative ability in vitro under conditions where survival pathways can be activated by adhesion to the substrate as shown by [ 3 H]-thymidine incorporation of cells grown in monolayer conditions. Moreover, NRAS Q61R clones displayed enhanced tumour growth in SCID mice. This feature was associated with the absence of extensive necrosis, as instead observed in tumours grown following inoculation of BRAF-mutated clones. This suggests that NRAS-mutated clones are better equipped to interact, for their own survival with extracellular matrix and with host stroma and vasculature, compared to BRAF-mutated clones. Given that the interplay between malignant cells and their microenvironment is critical for their growth (Hendrix et al., 2003; Bhowmick and Moses, 2005; Joyce, 2005) , it is therefore not unexpected that growth properties of a neoplastic population in soft agar and in vivo may not completely match. The growth properties of NRASmutated clones in vivo are in agreement with the known ability of oncogenic RAS to elicit an angiogenic phenotype, an activity that can be mediated by different soluble molecules (Watnick et al., 2003; Rak and Yu, 2004) . In fact, ectopic NRAS oncogene overexpression in a mouse tumour model has been shown to promote and sustain tumour survival (Sparman and Bar-Sagi, 2004) in part through CXCL-8/IL-8 production. In the same model, ablation of CXCL-8/IL-8 led to extensive tumour necrosis attributable to angiogenesis impairment. It cannot be ruled out, however, that the different behaviour of the two groups of clones could be modulated by associated genetic alterations.
The consequences of mutated BRAF and NRAS in human melanoma have been recently assessed, but only in terms of impact of these mutations on global gene expression (Pavey et al., 2004; Bloethner et al., 2005) . Mutation-specific gene expression profiles have been defined that indicate that the two mutations can signal not only through the common MAPK, but even by alternative signalling pathways and may confer tumours with distinct biological features. Microarray analysis coupled with RNAi silencing of oncogenes (Downward, 2004) will be needed to identify genes whose expression could influence soft-agar colony formation or in vivo tumour growth and, more importantly, the genetic programs regulated by NRAS or BRAF oncoproteins that, ultimately, might even shed light on the mechanisms responsible for preventing the occurrence of the two mutations in the same cell.
Materials and methods

Melanoma cell lines
Clinical and pathological information of melanoma specimens as well as mutational status regarding RAS genes and BRAF exons 11 and 15 of the corresponding short-term cell lines has been previously described (Lupetti et al., 1994; Daniotti et al., 2004) . Metastatic 665/1, 665/2, 665/R melanomas and primary 5810 melanoma led to the derivation of previously reported clonal cell lines (Anichini et al., 1989) . All these melanoma clones have been derived from the corresponding tumours after five in vitro passages with a two-layer soft-agarose technique (Anichini et al., 1989) . All cell lines were cultured at 371 in a humidified 7.5% CO 2 atmosphere, were routinely tested for the absence of Mycoplasma contamination by a PCR-based kit (Mycoplasma Plus PCR primer set, Stratagene) and were used when they reached 80% of confluency. Culture medium was RPMI 1640 (Biowhittaker), containing 1 mM sodium pyruvate, 2 mM glutamine, 50 mg/ml penicillin/streptomycin (complete medium) and supplemented with 10% heat inactivated FCS (Biowhittaker). In the experiments aimed to assess the ability of cells to survive in absence of adhesion, cells Genomic DNA extraction and MASA-PCR DNA was extracted according to standard protocols. MASA-PCR for the detection of BRAF V600E and NRAS Q61R was conducted with described primers designed to possess two bases substitution, in comparison to wild-type sequences, at the 3 0 -end, as previously published (Linard et al., 2002; Xu et al., 2003) . These primers were, respectively, F-1200-GGTGATTTTGGTCTAGCTACAAA for BRAF V600E and F-1204-ATACTGGATACAGCTGGAAG for NRAS
Q61R
. Forward primers used as positive control to amplify both wild-type as well as mutant sequences were F-1203-CAT ACTGGATACAGCTGGAC for NRAS exon 3 or F-1201-TAGGTGATTTTGGTCTAGCTACAGT for BRAF exon 15. Reverse (R) primers used for all PCR were R-1205-TGACTTGCTATTATTGATGG for NRAS and R-1202-GGCCAAAAATTTAATCAGTGGA for BRAF (Linard et al., 2002; Xu et al., 2003) . Amplifications were performed in a 25-ml PCR reaction mixture containing 2.5 mM of each dNTP, 0.1 mM concentration of each primer, 0.6 U of HotMaster Taq DNA polymerase (Eppendorf) and 100 ng/sample of genomic DNA template. The PCR reaction was set with an initial denaturation time of 3 min at 941C followed by cycled template denaturation of 20 s at 941C, primer annealing at 551C for 15 s, primer extension at 651C for 30 s and by a final elongation at 651C for 1 min. The reaction was run under standard conditions for 35 cycles. PCR products, all of the expected size (129 bp for BRAF
V600E
, 215 bp for BRAF wt , 106 bp for NRAS Q61R and for NRAS wt ) were electrophoresed through 1.5% agarose gels and stained with ethidium bromide. All negative samples in one of the two MASA-PCR at 35 cycles were re-examined under the same conditions but for 45 cycles.
PCR amplifications of BRAF exon 15 and NRAS exon 3 and sequencing For sequencing purposes amplifications were performed using the following couple of forward (F) and reverse (R) primers (Davies et al., 2002) for BRAF exon 15 (F1168/R1169) and NRAS exon 3 (F1163/R1165):
Amplifications were performed for 35 cycles as described for MASA-PCR except that Expand high fidelity PCR system (Roche) was used and analysis was performed in a 100 ml volume reaction. Amplified products were excised from agarose gels and purified using a QIAGEN QIAquick Gel Extraction Kit. The NRAS and BRAF PCR products were automatically sequenced using ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction (Applied Biosystems) with NRAS exon 3 F-644-GGTGAAACCTGTTTGTTGGA and R-1164-ATGACTTGCTATTATTGATGG, and BRAF exon 15 F-1166-TCATAATGCTTGCTCTGATAGGA and R-1202-GGCCAAAAATTTAATCAGTGGA sequencing primers.
Two-layer soft-agarose assay For clonogenic assay, 1 Â 10 5 cells were seeded in 400 ml of a liquid overlay agarose mixture (RPMI 1640, 10%FCS, 0.3% w/v agarose) into six-well flat-bottomed plates (Costar) coated with 400 ml of solidified underlay agarose (RPMI 1640, 10%FCS, 0.6% w/v agarose). After soft-agarose solidification, plates were incubated at 371 in 7.5% CO 2 . After 3 weeks, the colonies were counted under a microscope and photographed. Only multicellular aggregates were regarded as positive colonies. All experiments were performed twice using triplicate plates per experimental point.
Cell proliferation assay Cells were starved in serum-free medium overnight and were seeded in flat-bottom 96-well plates at 3 Â 10 4 cells/well in a volume of 100 ml in complete medium supplemented with different concentrations of FCS (10, 1, 0.1, 0%). At 12 h before harvesting onto glass fibre filters, 1 mCi of 3 [H]-thymidine (Perkin-Elmer) was added to each well. Cells were then trypsinized, harvested onto a glass fibre filter with the Harvester and the radioactivity incorporated into DNA was quantified using a scintillation counter (Wallac). The results shown represent the mean (counts per minute)7standard deviation of three replicates.
In vivo tumour growth assay and histochemistry Female CB.17 SCID/SCID mice aged 4-5 weeks (Harlan, Italy) were kept under specific pathogen-free conditions and housed in microisolator cages and all of the food, water, and bedding were autoclaved before use. Mice were injected subcutaneously into the right flank with 200 ml RPMI containing 5 Â 10 6 cells of melanoma clones cell suspensions. At least five mice were used for each group. Tumour dimensions were measured three times per week with calipers. Tumour weight was estimated using the formula: tumour weight (mg) ¼ length (mm) Â width 2 (mm)/2, as described (Lozupone et al., 2004) . All mice were killed at the end of the experiments, within 2 months after the injection of the human tumour cells (following the guidelines of the Istituto Superiore di Sanita`). Samples of tumours were processed for DNA extraction as well as paraffin-embedded and cut into 4 mm sections. After deparaffinization and rehydratation slides were stained with haematoxylin and eosin using standard methods and microscopically examined for histopathological features.
Statistical analysis
Statistical evaluation of data from cell proliferation, clonogenic assay and tumour weight in grafted SCID mice for NRAS Q61R or BRAF V600E melanoma clones was performed using the unpaired Student's t-test. Level of significance of tumour weight differences between tumour samples in the two groups was also calculated with one-way ANOVA. Only Pvalues of less than 0.01 were considered statistically significant.
